Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2002

View Archived Issues

NNC-45-0781, a promising candidate for postmenopausal osteoporosis

Antitumor effects demonstrated for rapamycin at immunosuppressive doses

Influenza vaccination reduces risk of brain infarction according to French researchers

Seattle Genetics and Genencor jointly develop ADEPT products including SGN-17/19

FDA approves BioPort anthrax vaccine license supplements

Preclinical evidence for efficacy of celecoxib in inflammatory bowel disease

Forbes Medi-Tech initiates phase I trial of cholesterol-lowering pharmaceutical

AltaRex offers further analysis of OvaRex results

Corixa reports progress in 2001

Malarex: a natural alternative in the fight against malaria

Chiron and Global Alliance for TB Drug Development collaborate on PA-824

Gleevec approved for gastrointestinal stromal tumors

National Institute on Aging studies genetic traits in Sardinians

Oxigene highlights product developments in fourth quarter 2001

First approval obtained for antihypertensive combination developed in Spain

Clinical testing of candidate HIV vaccine developed at GSK commences in U.S.

Tricyclic compounds that inhibit MRP-1 are useful as oncolytics

Radiolabeled nucleoside compounds for use as cancer imaging and therapeutic agents

Corixa designs isoleucine-containing peptide prodrugs of antitumor agents

Quinazoline derivatives that act as NPY antagonists for eating disorders, etc.

Preparation and use of pipecolic acid derivatives with MMP-inhibitory activity

Aromatic alphavbeta3 and/or alphavbeta5 integrin receptor antagonists disclosed by Pharmacia

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...